JPS6440428A - Antihyperlipemia - Google Patents

Antihyperlipemia

Info

Publication number
JPS6440428A
JPS6440428A JP62197735A JP19773587A JPS6440428A JP S6440428 A JPS6440428 A JP S6440428A JP 62197735 A JP62197735 A JP 62197735A JP 19773587 A JP19773587 A JP 19773587A JP S6440428 A JPS6440428 A JP S6440428A
Authority
JP
Japan
Prior art keywords
dha
derivative
substance
effects
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP62197735A
Other languages
Japanese (ja)
Inventor
Osamu Nishikaze
Yoshio Hayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DAIICHI YAKUHIN SANGYO KK
Original Assignee
DAIICHI YAKUHIN SANGYO KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DAIICHI YAKUHIN SANGYO KK filed Critical DAIICHI YAKUHIN SANGYO KK
Priority to JP62197735A priority Critical patent/JPS6440428A/en
Priority to IT8821626A priority patent/IT1226584B/en
Priority to AU20302/88A priority patent/AU616423B2/en
Priority to DE3826297A priority patent/DE3826297A1/en
Priority to KR1019880009978A priority patent/KR930001809B1/en
Priority to FR8810704A priority patent/FR2619009B1/en
Priority to GB8818776A priority patent/GB2208473A/en
Publication of JPS6440428A publication Critical patent/JPS6440428A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

PURPOSE:To obtain an antihyperlipemia showing improving effects on hyperlipemia, reinforcing action on vascular wall action and removing effects on blood platelet attached to vascular wall free from said effects, containing dehydroepiandrosterone or a derivative thereof as an active ingredient. CONSTITUTION:Dehydroepiandrosterone (DHA) or a derivative thereof as an active ingredient is pharmaceutically manufactured by a conventional procedure to give the aimed substance. The substance can be prepared into a dosage form such as tablet, granule or powder and a dose is 25-75mg/day in the case of oral administration. A DHA sulfate inclusion compound may be cited as the derivative of DHA. DHA is a well-know substance secreted as DHA-S, a kind of steroid hormone produced in adrenal cortex.
JP62197735A 1987-08-07 1987-08-07 Antihyperlipemia Pending JPS6440428A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP62197735A JPS6440428A (en) 1987-08-07 1987-08-07 Antihyperlipemia
IT8821626A IT1226584B (en) 1987-08-07 1988-08-02 ANTI-HYPERLIPEMIC AGENT
AU20302/88A AU616423B2 (en) 1987-08-07 1988-08-02 Anti-hyperlipemic agent
DE3826297A DE3826297A1 (en) 1987-08-07 1988-08-03 TREATMENT OF HYPERLIPIDAEMIA AND PREPARATION OF A MEDICAMENT HEREFUER
KR1019880009978A KR930001809B1 (en) 1987-08-07 1988-08-05 Anti-hyperlipemic agent
FR8810704A FR2619009B1 (en) 1987-08-07 1988-08-08 ANTI-HYPERLIPEMIC AGENT
GB8818776A GB2208473A (en) 1987-08-07 1988-08-08 Anti-hyperlipemic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP62197735A JPS6440428A (en) 1987-08-07 1987-08-07 Antihyperlipemia

Publications (1)

Publication Number Publication Date
JPS6440428A true JPS6440428A (en) 1989-02-10

Family

ID=16379469

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62197735A Pending JPS6440428A (en) 1987-08-07 1987-08-07 Antihyperlipemia

Country Status (7)

Country Link
JP (1) JPS6440428A (en)
KR (1) KR930001809B1 (en)
AU (1) AU616423B2 (en)
DE (1) DE3826297A1 (en)
FR (1) FR2619009B1 (en)
GB (1) GB2208473A (en)
IT (1) IT1226584B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016543A1 (en) * 1996-10-14 1998-04-23 Kanebo, Limited Remedy for chronic fatigue syndrome
JP2009143925A (en) * 2000-10-06 2009-07-02 Aeson Therapeutics Inc Compound useful for treatment of hypertriglyceridemia

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736537A (en) 1995-09-12 1998-04-07 Estee Lauder, Inc. Dehydroep:androsterone sailcylate useful against skin atrophy
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
FR2803519B1 (en) * 2000-01-12 2002-03-22 Assist Publ Hopitaux De Paris ORAL USE OF DEHYDROEPIANDROSTERONE, ITS PRECURSORS AND DERIVATIVES FOR IMPROVING THE PAPYRACE OF THE SKIN
WO2023156803A1 (en) * 2022-02-17 2023-08-24 Debreceni Egyetem Dhea-derived steroids

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6069096A (en) * 1983-08-02 1985-04-19 リサ−チ・コ−ポレイシヨン Novel steroid

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE439586B (en) * 1975-09-05 1985-06-24 Kanebo Ltd SET TO PREPARE A STABLE PHARMACEUTICAL DRY PREPARATION OF AN ALKALIMETAL SALT OF DEHYDROEPIANDROSTERON SULPHATE
US4496556A (en) * 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
US4666898A (en) * 1983-12-28 1987-05-19 Jackson Lab. Treatment of obesity, diabetes and other symptoms of hypercorticoidism using etiocholanolones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6069096A (en) * 1983-08-02 1985-04-19 リサ−チ・コ−ポレイシヨン Novel steroid

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016543A1 (en) * 1996-10-14 1998-04-23 Kanebo, Limited Remedy for chronic fatigue syndrome
JP2009143925A (en) * 2000-10-06 2009-07-02 Aeson Therapeutics Inc Compound useful for treatment of hypertriglyceridemia

Also Published As

Publication number Publication date
KR890003386A (en) 1989-04-14
FR2619009B1 (en) 1994-09-23
IT1226584B (en) 1991-01-24
KR930001809B1 (en) 1993-03-13
DE3826297A1 (en) 1989-02-16
IT8821626A0 (en) 1988-08-02
AU2030288A (en) 1989-02-09
AU616423B2 (en) 1991-10-31
GB8818776D0 (en) 1988-09-07
FR2619009A1 (en) 1989-02-10
GB2208473A (en) 1989-04-05

Similar Documents

Publication Publication Date Title
Waziri Glycine therapy of schizophrenia.
EP0163000A2 (en) Pharmaceutical product in pellet form with a continuous sustained release
CA2105165A1 (en) Dosage form for a delayed drug-delivery
ZA897977B (en) Contraception system and method
JPS5620509A (en) Long-acting pharmaceutical preparation for nasal cavity use, and method for manufacturing the same
EG19642A (en) A process for the preparation of oral composition for the treatment of inflammatory bowel diseases
ATE77947T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING PENTAMIDINE.
NZ229518A (en) Pharmaceutical dosage form for the medication of fish: method of administration and (prophylactic) treatment
Franchimont et al. THE EFFECT OF HYPOTHALAMIC LUTEINIZING HORMONE RELEASING HORMONE (LH‐RH) ON PLASMA GONADOTROPHIN LEVELS IN NORMAL SUBJECTS
JPS6440428A (en) Antihyperlipemia
Cushman Jr et al. Methadone-maintained patients. Effect of methadone on plasma testosterone, FSH, LH, and prolactin
Speck et al. Bio-availability and pharmacokinetics of cyproterone acetate-14C and ethinyloestradiol-3H after oral administration as a coated tablet (SH B 209 AB)
ATE135909T1 (en) METHOD FOR TREATING ACNE
CA2051369A1 (en) Thyroid hormone cardiac treatment
CA1065252A (en) Preparations and packs and new methods for the treatment of menopausal disturbed functions
JPS55122715A (en) Antidiabetic agent
EP0333678A3 (en) Use of glycerol ethers in the treatment of allergic diseases
US4795747A (en) 16-epiestriol to prevent, inhibit or reduce inflammation
JPS55136225A (en) Novel antiallergic agent
Hladovec et al. Oral contraceptives, methionine and endothelial lesion
JPS643121A (en) Remedy for endometriosis
EP0308909A3 (en) 1,3-dithiol-2-thiones or 1,3-dithiolane-2-thiones for curing hepatic disease
JPS55136224A (en) Novel antiallergic agent
Maia Jr et al. Mid-cycle contraception with LHRH in women
JPS5462327A (en) Remedy for dna virus infectious disease